Glenmark discovers new drug molecule; clinical trials by 2011

Glenmark Pharmaceuticals has discovered a new drug molecule, which could be used for treating pain and respiratory disorders. The new drug molecule, codenamed ‘GRC 17536’, has completed pre-clinical trials (animal tests) and will move into clinical trials (tests on humans) in the first quarter of 2011.

GRC 17536 is another potential first-in-class globally and the results shown by the molecule in animal studies is encouraging. It has proven highly efficacious in treating inflammatory and neuropathic pain in animal models, compared to gold standard drugs. Glenmark has already filed multiple patent applications for these molecules. The company’s Novel Chemical Entity (NCE) programme is targeting pain and respiratory disorders.